Limits...
Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer's disease.

Zhu Y, Li C, Sun A, Wang Y, Zhou S - Exp Ther Med (2015)

Bottom Line: The results revealed that the mRNA and protein expression levels of VEGF in the CSF and serum were decreased in the MCI and AD groups compared with those in the control group.The greater the severity of the dementia, the lower the mRNA and protein expression of VEGF.Similar to the trend observed for VEGF, the miRNA-210 expression in the CSF and serum decreased as the severity of the AD increased. miRNA-210 is thus not only indicative of AD pathogenesis, but may also provide novel insights into the prevention and treatment of the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of ICU, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.

ABSTRACT

The aim of the present study was to investigate the potential clinical application of the genetic marker microRNA (miRNA)-210 in the cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD). The enrolled patients were divided into the mild cognitive impairment (MCI) and AD groups. Healthy individuals were used as the controls. The mRNA and protein expression of vascular endothelial growth factor (VEGF) in the CSF and serum samples was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. The expression of miRNA-210 in the CSF and serum was detected by RT-qPCR. The results revealed that the mRNA and protein expression levels of VEGF in the CSF and serum were decreased in the MCI and AD groups compared with those in the control group. The greater the severity of the dementia, the lower the mRNA and protein expression of VEGF. Similar to the trend observed for VEGF, the miRNA-210 expression in the CSF and serum decreased as the severity of the AD increased. miRNA-210 is thus not only indicative of AD pathogenesis, but may also provide novel insights into the prevention and treatment of the disease.

No MeSH data available.


Related in: MedlinePlus

Changes in the expression levels of VEGF mRNA and protein in the serum of patients with dementia. (A) mRNA expression of VEGF in the serum of patients with dementia was measured by the reverse transcription-quantitative polymerase chain reaction. (B) VEGF protein expression in the serum of patients with dementia was detected through western blot analysis. (C) Statistical analysis of VEGF protein expression in the serum. Compared with the control group, *P<0.05 and **P<0.01; compared with the MCI group, #P<0.05 and ##P<0.01. MCI, mild cognitive impairment; AD, Alzheimer’s disease; VEGF, vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4316946&req=5

f2-etm-09-03-1013: Changes in the expression levels of VEGF mRNA and protein in the serum of patients with dementia. (A) mRNA expression of VEGF in the serum of patients with dementia was measured by the reverse transcription-quantitative polymerase chain reaction. (B) VEGF protein expression in the serum of patients with dementia was detected through western blot analysis. (C) Statistical analysis of VEGF protein expression in the serum. Compared with the control group, *P<0.05 and **P<0.01; compared with the MCI group, #P<0.05 and ##P<0.01. MCI, mild cognitive impairment; AD, Alzheimer’s disease; VEGF, vascular endothelial growth factor.

Mentions: To further confirm the association between VEGF expression and the pathogenesis of AD, the serum expression of VEGF was determined. The RT-qPCR results showed that the serum expression level of VEGF mRNA was significantly lower in the MCI group than that in the control group (P<0.05) (Fig. 2A). In the AD group, the serum VEGF mRNA expression was further decreased and was significantly different from that in the MCI group (P<0.01) (Fig. 2A). Western blot analysis demonstrated that the protein expression level of VEGF in the serum was markedly lower in the MCI group than that in the control group (P<0.05), and it was further decreased in the AD group (P<0.01) (Fig. 2B and C). These results indicate that the VEGF mRNA and protein expression levels in the serum decrease with the increase in disease severity.


Quantification of microRNA-210 in the cerebrospinal fluid and serum: Implications for Alzheimer's disease.

Zhu Y, Li C, Sun A, Wang Y, Zhou S - Exp Ther Med (2015)

Changes in the expression levels of VEGF mRNA and protein in the serum of patients with dementia. (A) mRNA expression of VEGF in the serum of patients with dementia was measured by the reverse transcription-quantitative polymerase chain reaction. (B) VEGF protein expression in the serum of patients with dementia was detected through western blot analysis. (C) Statistical analysis of VEGF protein expression in the serum. Compared with the control group, *P<0.05 and **P<0.01; compared with the MCI group, #P<0.05 and ##P<0.01. MCI, mild cognitive impairment; AD, Alzheimer’s disease; VEGF, vascular endothelial growth factor.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4316946&req=5

f2-etm-09-03-1013: Changes in the expression levels of VEGF mRNA and protein in the serum of patients with dementia. (A) mRNA expression of VEGF in the serum of patients with dementia was measured by the reverse transcription-quantitative polymerase chain reaction. (B) VEGF protein expression in the serum of patients with dementia was detected through western blot analysis. (C) Statistical analysis of VEGF protein expression in the serum. Compared with the control group, *P<0.05 and **P<0.01; compared with the MCI group, #P<0.05 and ##P<0.01. MCI, mild cognitive impairment; AD, Alzheimer’s disease; VEGF, vascular endothelial growth factor.
Mentions: To further confirm the association between VEGF expression and the pathogenesis of AD, the serum expression of VEGF was determined. The RT-qPCR results showed that the serum expression level of VEGF mRNA was significantly lower in the MCI group than that in the control group (P<0.05) (Fig. 2A). In the AD group, the serum VEGF mRNA expression was further decreased and was significantly different from that in the MCI group (P<0.01) (Fig. 2A). Western blot analysis demonstrated that the protein expression level of VEGF in the serum was markedly lower in the MCI group than that in the control group (P<0.05), and it was further decreased in the AD group (P<0.01) (Fig. 2B and C). These results indicate that the VEGF mRNA and protein expression levels in the serum decrease with the increase in disease severity.

Bottom Line: The results revealed that the mRNA and protein expression levels of VEGF in the CSF and serum were decreased in the MCI and AD groups compared with those in the control group.The greater the severity of the dementia, the lower the mRNA and protein expression of VEGF.Similar to the trend observed for VEGF, the miRNA-210 expression in the CSF and serum decreased as the severity of the AD increased. miRNA-210 is thus not only indicative of AD pathogenesis, but may also provide novel insights into the prevention and treatment of the disease.

View Article: PubMed Central - PubMed

Affiliation: Department of ICU, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277102, P.R. China.

ABSTRACT

The aim of the present study was to investigate the potential clinical application of the genetic marker microRNA (miRNA)-210 in the cerebrospinal fluid (CSF) and serum of patients with Alzheimer's disease (AD). The enrolled patients were divided into the mild cognitive impairment (MCI) and AD groups. Healthy individuals were used as the controls. The mRNA and protein expression of vascular endothelial growth factor (VEGF) in the CSF and serum samples was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis, respectively. The expression of miRNA-210 in the CSF and serum was detected by RT-qPCR. The results revealed that the mRNA and protein expression levels of VEGF in the CSF and serum were decreased in the MCI and AD groups compared with those in the control group. The greater the severity of the dementia, the lower the mRNA and protein expression of VEGF. Similar to the trend observed for VEGF, the miRNA-210 expression in the CSF and serum decreased as the severity of the AD increased. miRNA-210 is thus not only indicative of AD pathogenesis, but may also provide novel insights into the prevention and treatment of the disease.

No MeSH data available.


Related in: MedlinePlus